research Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
Talquetamab may cause hair loss and skin issues.
Search
for
Sort by
Research
390-420 / 1000+ results research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing
A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
research Treatment strategies for alopecia
Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Recent approaches of antibody therapeutics in androgenetic alopecia
Antibody treatments show promise for hair loss but need more research.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis: Results from a large cross-sectional cohort study
Adults with alopecia areata stick to their medication better than those with atopic dermatitis.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Use of adapalene in alopecia areata: Efficacy and safety of mometasone furoate 0.1% cream versus combination of mometasone furoate 0.1% cream and adapalene 0.1% gel in alopecia areata
Combining mometasone furoate cream with adapalene gel is safer and more effective for hair regrowth in alopecia areata than using the cream alone.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Alefacept for Alopecia Areata
Alefacept showed some effectiveness for alopecia areata but needs more research.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research Dupliumab therapy for alopecia areata: a case series and review of the literature
Dupilumab may help treat alopecia areata without needing high IgE levels.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Case of alemtuzumab-related alopecia areata management in MS
Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
The study investigated the effects of IMG-007, an anti-OX40 monoclonal antibody, on patients with severe alopecia areata (AA). In this phase 1b/2a open-label study, 29 participants received either 300 mg or 600 mg doses of IMG-007. The 600 mg group showed significant improvement in hair regrowth, with a progressive reduction in SALT scores up to week 36, while the 300 mg group showed little change. IMG-007 was well-tolerated, with only mild or moderate adverse events. Biomarker analysis revealed normalization of inflammatory gene expression and partial restoration of hair-associated keratin genes. These findings suggest that IMG-007 could be an effective treatment for AA by blocking OX40-OX40L signaling.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research Dupilumab Induced Hair Regrowth in Alopecia Totalis
Dupilumab may help regrow hair in people with severe alopecia.
research An unusual presentation of X-linked adrenoleukodystrophy
A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.